Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
在既往未接受治疗的慢性淋巴细胞白血病 (CLL) 患者中，采用氟达拉滨和利妥昔单抗联合递增剂量的来那度胺治疗，随后进行来那度胺/利妥昔单抗维持治疗：REVLIRIT CLL-5 AGMT I/II 期研究
期刊:Annals of Hematology
影响因子:2.4
doi:10.1007/s00277-018-3380-z
Egle, Alexander; Steurer, Michael; Melchardt, Thomas; Weiss, Lukas; Gassner, Franz Josef; Zaborsky, Nadja; Geisberger, Roland; Catakovic, Kemal; Hartmann, Tanja Nicole; Pleyer, Lisa; Voskova, Daniela; Thaler, Josef; Lang, Alois; Girschikofsky, Michael; Petzer, Andreas; Greil, Richard
